Medexus Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Medexus Pharmaceuticals's estimated annual revenue is currently $22.3M per year.
- Medexus Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Medexus Pharmaceuticals has 111 Employees.
- Medexus Pharmaceuticals grew their employee count by -3% last year.
Medexus Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.1M | 65 | 30% | N/A | N/A |
#2 | $75.6M | 376 | 7% | N/A | N/A |
#3 | $23.9M | 119 | 13% | $35M | N/A |
#4 | $12.7M | 63 | -3% | N/A | N/A |
#5 | $5.4M | 27 | -25% | N/A | N/A |
#6 | $6M | 30 | -35% | N/A | N/A |
#7 | $6.6M | 33 | -8% | N/A | N/A |
#8 | $13.5M | 67 | -3% | N/A | N/A |
#9 | $186.3M | 927 | 19% | N/A | N/A |
#10 | $4.4M | 22 | -4% | N/A | N/A |
What Is Medexus Pharmaceuticals?
Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.
keywords:N/A
N/A
Total Funding
111
Number of Employees
$22.3M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Medexus Pharmaceuticals News
2022-04-20 - Keeping Track: TGT's Ukoniq Is Latest PI3K Inhibitor To Fall ...
Medexus Pharmaceuticals and its partner medac announced the CRL in August 2021 for treosulfan in combination with fludarabine as part of a...
2022-04-20 - Medexus Pharmaceuticals Announces Resubmission of ...
Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA. April 22, 2022 08:30 ET | Source: Medexus Pharmaceuticals Inc Medexus Pharmaceuticals Inc.
2022-04-17 - Medexus to Present at the Bloom Burton & Co. Healthcare ...
TORONTO and CHICAGO, April 19, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) will be presenting at...
Other Companies in Chicago
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15.5M | 111 | 8% | N/A |
#2 | $17.8M | 111 | 5% | N/A |
#3 | $1760M | 111 | 12% | $623M |
#4 | $27.9M | 111 | 42% | N/A |
#5 | $30M | 111 | 5% | N/A |